Brief: Oncoquest initiates commercial scale Oregovomab manufacturing program

Quest PharmaTech

07/12/2016 21:31

Dec 7 (Reuters) - Quest Pharmatech Inc  QPT.V  
    * Oncoquest initiates commercial scale Oregovomab 
manufacturing program for treatment of ovarian cancer 
    * Says additional phase ii clinical trial using Oregovomab 
in combination with a TLR3 agonist, hiltonol being initiated in 
U.S. 
    * Signs agreement with Cytovance for development of 
commercial scale antibody manufacturing, with Veristat for 
clinical trial management 
 
Source text for Eikon:  ID:nPn3hy9qSa  
Further company coverage:  QPT.V  
 
 ((Bangalore.newsroom@thomsonreuters.com;))